Takeda has entered into deals with two biotechs, TiGenix and Denali Therapeutics, to bolster its pipeline in two of core therapy areas of focus - gastroenterology and central nervous system (CNS). The acquisition of TiGenix for EUR520 M will give Takeda worldwide rights to Cx601 (darvadstrocel), a Phase III allogeneic stem cell therapy, which Takeda had already licensed from TiGenix, for complex perianal fistulas in patients with Crohn’s disease in non-US territories. The agreement with Denali is worth upto US$1.173 B and involves licensing three genetically-targeted programmes, BACE1/Tau, TREM2 and an undisclosed candidate, to grow its neurodegenerative disorders business.